Regulus Therapeutics Inc. (RGLS) is on the roll with an average volume of 2.53M in the recent 3 months

Regulus Therapeutics Inc. (RGLS) is priced at $1.39 after the most recent trading session. At the very opening of the session, the stock price was $1.53 and reached a high price of $1.5369, prior to closing the session it reached the value of $1.47. The stock touched a low price of $1.38.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Recently in News on February 10, 2021, Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced it has completed enrollment of the first cohort of patients into its Phase 1b clinical study of RGLS4326. The Phase 1b is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD. The study is designed to evaluate the safety, pharmacokinetics, and changes in levels of polycystin 1 (PC1) and polycystin 2 (PC2) in patients with ADPKD administered RGLS4326 every other week for a total of four doses. The dose level for the first cohort is 1mg/kg of RGLS4326 and the dose level for the second cohort is 0.3mg/kg. The third and final cohort will be dosed at a level to be determined based on the results of the first two cohorts. Concurrent with completion of enrollment in the first cohort and based on the review of the available interim safety data, the first patient of the second cohort has received the first dose of RGLS4326. You can read further details here

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .


Regulus Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.9700 on 02/17/21, with the lowest value was $1.1100 for the same time period, recorded on 01/13/21.

Regulus Therapeutics Inc. (RGLS) full year performance was 78.43%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Regulus Therapeutics Inc. shares are logging -29.44% during the 52-week period from high price, and 229.23% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.42 and $1.97.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2287598 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Regulus Therapeutics Inc. (RGLS) recorded performance in the market was 2.96%, having the revenues showcasing 120.63% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 52.97M, as it employees total of 24 workers.

Regulus Therapeutics Inc. (RGLS) in the eye of market guru’s

During the last month, 0 analysts gave the Regulus Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 0.9914, with a change in the price was noted +0.8760. In a similar fashion, Regulus Therapeutics Inc. posted a movement of +170.43% for the period of last 100 days, recording 1,756,813 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RGLS is recording 1.74 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Regulus Therapeutics Inc. (RGLS): Stocks Technical analysis and Trends

Raw Stochastic average of Regulus Therapeutics Inc. in the period of last 50 days is set at 40.49%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 18.31%. In the last 20 days, the company’s Stochastic %K was 37.30% and its Stochastic %D was recorded 57.48%.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

If we look into the earlier routines of Regulus Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 2.96%. Additionally, trading for the stock in the period of the last six months notably improved by 146.06%, alongside a boost of 78.43% for the period of the last 12 months. The shares increased approximately by -23.20% in the 7-day charts and went down by 8.59% in the period of the last 30 days. Common stock shares were driven by 120.63% during last recorded quarter.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.